$PSYC announced that Psychedelic Spotlight has distributed to its subscribers the first edition of its Micro-Dose Monthly newsletter as part of the Company’s next step in developing its platform as a leading communications channel for the emerging industry of medicinal psychedelics. The newsletter is the culmination of the company’s insights to introduce the important work being done within the psychedelic space.

Not only are psychedelics showing promise as FDA-designated “breakthrough therapies,” but they may also be key to expanding consciousness through scientific discoveries on how these substances interact with the brain, and now, the accelerated progress of these studies have just created unprecedented investment opportunities with the industry’s leading companies going public this year. Psychedelics is providing hope for millions with the potential to treat mental health disorders